Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification

Jan C. Brase(Novartis (Switzerland)), Ulrike Korf(German Cancer Research Center)

Proteome Science

June 22, 2010

10.1186/1477-5956-8-36

Cited by 19

Related Papers

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

|Zurich Open Repository and Archive (University of Zurich)|2022|146

Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs

|Oncogenesis|2012|84

Synergism between Hedgehog-GLI and EGFR Signaling in Hedgehog-Responsive Human Medulloblastoma Cells Induces Downregulation of Canonical Hedgehog-Target Genes and Stabilized Expression of GLI1

|PLoS ONE|2013|83

LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial

|Annals of Oncology|2020|68

Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial.

|Journal of Clinical Oncology|2018|1